Antileishmanial Drug Discovery and Resistance Mechanisms
This community focuses on developing new treatments for leishmaniasis, a group of parasitic diseases, and understanding why current drugs fail. The work combines the design of new chemical compounds with clinical studies on how the parasite develops resistance to existing therapies.
The research centers on identifying molecules that inhibit Leishmania species, particularly L. infantum, L. major, and L. donovani. Recurring methods include molecular docking, virtual screening, and the synthesis of chemical derivatives to test for antileishmanial activity. The community also investigates drug resistance mechanisms and evaluates the efficacy of standard treatments like meglumine antimoniate and sodium stibogluconate. While Trypanosoma cruzi and Plasmodium falciparum appear in the literature, the core focus remains on leishmaniasis, with a specific emphasis on cutaneous and visceral forms of the disease.
The largest share of the community's output is found in antimony research, accounting for 2.6% of all antimony research, and 1,171 papers here. Sodium and oxygen also appear frequently, with 574 and 340 papers respectively, reflecting the chemical composition of standard antimonial drugs.
The community comprises 9,671 papers, publishing primarily in PLoS neglected tropical diseases, Antimicrobial Agents and Chemotherapy, and Memórias do Instituto Oswaldo Cruz.
Recent work continues to focus on leishmaniasis, including studies on drug resistance mechanisms, vaccine development, and the evaluation of new chemical derivatives through in silico and in vitro methods.